Health Services Research
The research projects at the Charité Comprehensive Cancer Center (CCCC) aim to continuously improve the care of patients diagnosed with cancer.
Factors that cause and/or promote the development of cancer are being investigated so that cancer early detection and prevention measures can subsequently be optimized for all.
You are here:
Research projects and working groups at the Charité Comprehensive Cancer Center
With its interdisciplinary approach, the Charité Comprehensive Cancer Center is ideal for research into the care of tumor patients. We focus on the local catchment area with an emphasis on socio-political and socio-relevant aspects of the care of tumor patients.
Here you can find information about the research projects and working groups in the field of health service research at the Charité Comprehensive Cancer Center.
Precision oncology aims to make individualized treatment recommendations based on genomic alterations. In addition, implicit similarities of individual patients are included in clinical decisions without a defined systematic approach. These similarities can be defined based on different types of data, including primary patient characteristics, past clinical history, histopathological findings, or molecular profiles such as genomic variants or expression signatures.
Precision oncology is part of the molecular and immunological tumor board (MiTB) of the Charité since 2016. Since the start of the MiTB, patient data is collected systematically and continuously documented in the tumor documentation system, leading to an ideal and diverse data basis for precision oncology.
In the newly GB-A funded project IntSim-Onko, we aim to integrate these relevant multimodal datasets, define similarity between patients systematically, and make the results available as a clinical decision-support. IntSim-Onko is an interdisciplinary consortium with partners from Charité, Humboldt Universität, and the Berlin Institute of Health. The corresponding partners will develop methods in their subject area, including data harmonization, text mining, and machine learning, which will build the framework for defining similarities between patients.
Together with the molecular and immunological tumor board, we will use the available rich data sets to validate our results, discuss with clinicians, and sharpen the focus of the methods developed. As a result, we hope that indications can be substantiated or restricted to sharpen therapy recommendations in precision oncology.
Contact: Dr. Manuela Benary
